Open AccessSurvival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies
Author(s) -
Zachary R. McCaw,
Lü Tian,
Dae Hyun Kim,
A. Russell Localio,
L. J. Wei
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1563
Subject(s) - medicine , covid-19 , coronavirus , pandemic , betacoronavirus , intensive care medicine , disease , virology , coronavirus infections , infectious disease (medical specialty) , outbreak
For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom